Home > Insider Trading > Filing (0001104659-19-077405)

Filing Details

Accession Number:: 0001104659-19-077405
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2019-12-31 19:11:00
Reporting Period:: 2019-12-27

Accepted Time:: 2019-12-31 19:11:00
Original Submission Date:: 2019-12-31
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1744659	Akero Therapeutics Inc.	AKRO	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1687880	Versant Venture Capital Vi, L.p.	One Sansome Street, Suite 3630 San Francisco CA 94104		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2019-12-27	33,256	$22.58	4,012,711	No	4	S	Direct
Common Stock	Disposition	2019-12-30	338,919	$24.39	3,673,792	No	4	S	Direct
Common Stock	Disposition	2019-12-31	17,207	$23.48	3,656,585	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan.
These sales were executed in multiple trades at prices ranging from $21.56 to $23.52. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
These sales were executed in multiple trades at prices ranging from $22.98 to $33.61. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
These sales were executed in multiple trades at prices ranging from $21.99 to $26.42. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer.
These shares are owned directly by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, LP ("Versant GP LP") is the general partner of Versant VI and Versant Ventures VI GP-GP, LLC ("Versant GP LLC") is the general partner of Versant GP LP and the ultimate general partner of Versant VI. Versant GP LP and Versant GP LLC may be deemed to have voting and investment power over the securities held by Versant VI and as a result may be deemed to have beneficial ownership over such securities.